الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 131 |  |  |
| | | from | 131 | | |
Abstract
Aim of the work
The aim of this work is to study the evidence of the presence of Islet cell antibodies (ICA) in type 2 diabetic patients. We applied one of the most widely used for the diagnosis and prediction of type 1 diabetes, namely ICA512 (IA-2) antibodies , in a well characterized population of type 2 in patients over the age of 50 years.
In our study we aimed detect the presence of ICA in the sera of elderly patients recently diagnosed with VIDDM, and to show the relation between the presence of antibodies and the serum level of C-peptide as an indicator for the function of cells, and also if there is a relation between the presence of this autoantibodies. Also the presence of CRP as a marker of inflammation in these patients was studied.
Conclusion
In summary, IA-2 autoantibodies in identifying a subgroup (8.3%) of individuals with autoimmune diabetes in older patients with impaired glycemic control, as they had higher blood glucose level either fasting or 2H postprandial than those who are negative for islet cell autoantibodies.
This estimate might be even higher when additional markers of islet cell autoimmunity and inflammation are applied to further define LADA in older populations.
This subgroup also has low serum level of C-peptide as compared with the ICA-ve diabetic patients; this may be due to destruction of β cells of the islets of Langerhans.
This subgroup also has higher body mass index than the ICA-ve diabetic patients.
This subgroup seems to have a marked activation of the acute phase response (i.e. CRP), which may be due to insulitis.
In conclusion, our observations may provide new insight to an adequate classification and treatment of type 2 diabetes and in turn lead to better knowledge and understanding of the autoimmune/ inflammatory mechanisms involved in autoimmune diabetes.